 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H21N3O |
| Molar mass | 283.375 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RTI-126 (RTI-4229-126 or(–)-2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane) is aphenyltropane derivative which acts as a potentmonoaminereuptake inhibitor andstimulant drug, and has been sold as adesigner drug. It is around 5 times more potent thancocaine at inhibiting monoamine reuptakein vitro, but is relatively unselective. It binds to all three monoamine transporters, although still with some selectivity for thedopamine transporter.[1] RTI-126 has a fast onset of effects and short duration of action, and its pharmacological profile in animals is among the closest to cocaine itself out of all the drugs in the RTI series. Its main application in scientific research has been in studies investigating the influence ofpharmacokinetics on the abuse potential of stimulant drugs, with its rapid entry into the brain thought to be a key factor in producing its high propensity for development of dependence in animals.[2][3]
The structurally related compound (–)-2β-(3-methyl-5-isoxazolyl)nortropane is a potent and selective agonist fornicotinic acetylcholine receptors, with twice the potency ofnicotine.[4]
nortropane_structure.png)